| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1106015503 |
| P356 | DOI | 10.1186/S13148-018-0539-3 |
| P932 | PMC publication ID | 6080402 |
| P698 | PubMed publication ID | 30081950 |
| P50 | author | Rowaida Z Taha | Q57903071 |
| Eyad Elkord | Q47163713 | ||
| P2093 | author name string | Salman M Toor | |
| Varun Sasidharan Nair | |||
| Hibah Shaath | |||
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| Results and challenges of immune checkpoint inhibitors in colorectal cancer. | Q52689522 | ||
| Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. | Q53534960 | ||
| DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. | Q55425717 | ||
| CpG island methylator phenotype in cancer | Q81080870 | ||
| Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1 | Q24316558 | ||
| Natural selection of tumor variants in the generation of "tumor escape" phenotypes | Q24551158 | ||
| Cancer immunoediting from immune surveillance to immune escape | Q24655415 | ||
| Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting | Q26742012 | ||
| Immune Checkpoint Blockade in Cancer Therapy | Q26830509 | ||
| Connections between TET proteins and aberrant DNA modification in cancer | Q26865671 | ||
| Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer | Q29622925 | ||
| A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing | Q33268624 | ||
| CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future | Q33337445 | ||
| Intratumoral FoxP3+Helios+ Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer | Q33729278 | ||
| Combination cancer immunotherapy and new immunomodulatory targets | Q34487698 | ||
| Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens | Q34788858 | ||
| Augmenting antitumor immune responses with epigenetic modifying agents | Q35048054 | ||
| Epigenetics and colorectal cancer | Q36081553 | ||
| Recurrent R-spondin fusions in colon cancer | Q36949683 | ||
| TETonic shift: biological roles of TET proteins in DNA demethylation and transcription | Q37244379 | ||
| DNA Demethylation of the Foxp3 Enhancer Is Maintained through Modulation of Ten-Eleven-Translocation and DNA Methyltransferases | Q37575781 | ||
| Loss of 5-hydroxymethylcytosine in cancer: cause or consequence? | Q38245387 | ||
| Cancer Statistics, 2017. | Q39038674 | ||
| TET family dioxygenases and DNA demethylation in stem cells and cancers | Q39268149 | ||
| Immune Checkpoints as a Target for Colorectal Cancer Treatment. | Q39387816 | ||
| Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21. | Q39867000 | ||
| PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes | Q40745198 | ||
| Epigenetic changes in colorectal cancer | Q41973340 | ||
| Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells | Q49851572 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | molecular biology | Q7202 |
| colorectal cancer | Q188874 | ||
| colorectal carcinoma | Q25493920 | ||
| P304 | page(s) | 104 | |
| P577 | publication date | 2018-08-06 | |
| P1433 | published in | Clinical Epigenetics | Q18620113 |
| P1476 | title | DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer | |
| P478 | volume | 10 |
| Q93264969 | Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy |
| Q99638160 | Genome-wide DNA methylation analysis by MethylRad and the transcriptome profiles reveal the potential cancer-related lncRNAs in colon cancer |
| Q90677742 | Immunogenic cell death in colon cancer prevention and therapy |
| Q64057809 | Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer |
| Q64120108 | PD-L1 Expression in Human Breast Cancer Stem Cells Is Epigenetically Regulated through Posttranslational Histone Modifications |
| Q98224804 | Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression |
| Q92310206 | Systematic analysis of differentially methylated expressed genes and site-specific methylation as potential prognostic markers in head and neck cancer |
Search more.